Full Press Release Details
Ticker: MRIC Investor Presentation
August 18, Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI 2016 MRI
INTERVENTIONS, INC. | 1
Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements often can
be identified by words such as "anticipates," "believes," "could," "estimates,"
"expects," "intends," "may," "plans," "potential," "predicts,"
"projects," "should," "will," "would," or the negative of these words or other
words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain
and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially
from those expressed in or implied by MRI Interventions' forward-looking statements. Particular uncertainties and risks include,
among others: demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity
from, our sales, clinical support and marketing capabilities; availability and adequacy of reimbursement from third party payors
for procedures utilizing our products; the sufficiency of our cash resources to maintain planned commercialization efforts and
research and development programs; future actions of the FDA or any other regulatory body that could impact product development,
manufacturing or sale; our ability to protect and enforce our intellectual property rights; our dependence on collaboration partners;
the impact of competitive products and pricing; the impact of the commercial and credit environment on us and our customers and
suppliers; and our ability to successfully complete the development of, and to obtain regulatory clearance or approval for, our
ClearTrace system. More detailed information on these and additional factors that could affect MRI Interventions' actual results
and the timing of events are described in its filings with the Securities and Exchange Commission. Except as required by law,
we undertake no obligation to publicly update or revise any forward-looking statements made in this presentation to reflect any
change in our expectations or any change in events, conditions or circumstances on which any such statements are based.
2016 MRI INTERVENTIONS, INC. | 2
Interventions Investment Opportunity Commercial Business Focused commercial effort in neurosurgery; FDA/CE cleared products Enabling
real-time MRI guided surgery; FDA-cleared, CE- marked and 45+ ClearPoint sites; growing procedure business Drug Delivery Upside
Growing Presence in Drug Delivery ClearPoint System now in 7 clinical trials; biotech like upside Investment TimingRestructuring
complete; operating cash burn dramatically lower. Several near-term milestones: 1 for 40 reverse split completed in July 2016
St. Jude's entry into the DBS market in the US - Q3/Q4 2016 Voyager reports results of first 10 patients - Q4,
2016* UniQure initiates second cohort of Phase 1 trial - Q1, 2017 Additional drug delivery partnerships under evaluation
* Estimated date 2016 MRI INTERVENTIONS, INC. | 3
Medical Device Leadership Team Key Management Executive Frank Grillo Peter Piferi Wendelin Maners Robert Korn Hal Hurwitz
Title President, CEO COO VP Marketing VP Sales CFO Prior Experience Board of Directors Kimble Jenkins, Maria Sainz
Dr. Phillip Pizzo Pascal Girin Timothy Frank Grillo, Chairman Richards CEO Jack Spencer Charles Koob Andrew Rooke Major Investor
2016 MRI INTERVENTIONS, INC. | 4
Neuro Navigation System Utilizes an existing diagnostic or intraoperative MRI to enable real time, intra-operative MRI
Imaging during Neurosurgery ClearPoint Software Proprietary software for targeting and trajectory calculation / determination
Dicom image based MRI Safe Hardware MRI safe head fixation frame, monitor, other components for the procedure SmartFrame ;
SmartGrid Single use devices, with MRI fiducials "seen" in MRI images, enable targeting and trajectory calculations
Proprietary drape for creating sterile environment Per procedure revenue Compatible with All Major MRI Platforms
2016 MRI INTERVENTIONS, INC. | 5
Procedures for Our Technology and the challenges we address Therapies Deep Brain Stimulation Medtronic St. Jude*
Boston Scientific* Laser Ablation Visualase/Medtronic Monteris Drugs/Biologics Voyager UniQure Merrimack Int'l Stem Cell
Medicenna Plus others Patient Populations Parkinson's Disease Dystonia Epilepsy Brain Tumor Parkinson's Disease Brain
Tumor Key Challenges We Address 65% plus opt-out rate for DBS due to fear of surgery itself Two room procedure Patient transport
mid-procedure Accuracy of ablation is critical Precise, Controlled Delivery is Essential Drug diffusion visualization is a must
have Need for ClearPoint underscored in Voyager S-1 2016 MRI INTERVENTIONS, INC. | 6
ClearPoint, Minimally Invasive Neuro Procedures Are Performed "Blind" Conventional Stereotactic Procedure No real
time images - images from earlier in the day or week ClearPoint Neuro Procedure 80% of interviewed neurosurgeons/neurologists
believe real time MRI-guidance will or can become the future of functional neurosurgery. (*) *Interviews conducted by
a third party on behalf of MRI Interventions (n=36) 2016 MRI INTERVENTIONS, INC. | 7
Procedure Overview Target Selection & Entry Planning 2016 MRI INTERVENTIONS, INC. | 8
Procedure Overview SmartFrame Trajectory Guide SmartFrame Hand Controller Trajectory Alignment & Device Insertion
2016 MRI INTERVENTIONS, INC. | 9
Support, Validation Notable Neurosurgeon Supporters Dr. Philip Starr ASSFN Past President Dr. Paul Larson UCSF & VA
Dr. Robert Gross Emory University Dr. Robert Wharen, Jr. Mayo Clinic - Jacksonville Dr. Krys Bankiewicz Bankiewicz Lab, UCSF Dr.
Russ Lonser OSU - NIH Published Peer-Reviewed Journal Support 2016 MRI INTERVENTIONS, INC. | 10
Intellectual Property Over 100 issued patents around the world 20+ U.S. 30+ OUS 70+ U.S. Patents 45+ OUS Patents Patent
Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software
and devices; the SmartFrame trajectory guide; other ClearPoint disposable components; active intracranial probes; MRI-compatible
catheters and Hand Drill; MRI-safety technology; Scalp Mount Base Key ClearPoint-related patents do not begin to expire until
2027 2016 MRI INTERVENTIONS, INC. | 11
Unique Opportunity in Drug Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery
(pills, shots, IV) of almost all drugs - 98% of small molecules - Direct injection without ClearPoint is blind, so target
is frequently missed - Neopharm Trial - 51% of 572 catheters failed to meet all positioning criteria Major Benefits
of Drug Delivery with ClearPoint - Neurosurgeon sees that target is reached - Eliminates the blood brain barrier issue - Reduces/eliminates
unwanted systemic side effects - Reduces dosage levels (as little as 1/300th of systemic volume) Business Model - MRIC Partners
with Drug Companies and Researchers - MRIC provides ClearPoint; Drug company provides drug candidate - Drug company/sponsor pays
for trial - If drug is approved, MRIC gets device revs (~$7000/case); Drug co gets drug revs Provides MRIC with "biotech-like
upside" without "all or nothing downside" 2016 MRI INTERVENTIONS, INC. | 12
Drug Delivery w/ SmartFlow Cannula MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered
under MR-guidance* Specialized, FDA-cleared drug delivery cannula's / catheters Drug infusion is visible
under real- time MRI Growing Set of Peer-reviewed Publications Conclusion: The ClearPoint system allows
Real-time Convection- enhanced Delivery to be performed with a high level of precision, predictability, and safety. * CAUTION:
SmartFlow Cannula is approved for injection of Cytarabine or removal of CSF from the ventricles during intracranial procedures.
Uses other than the approved indication are limited by Federal law to investigational use. 2016 MRI INTERVENTIONS, INC.
Use in Drug Delivery Seven Programs Underway Now... Current Drug Delivery Trials Utilizing the ClearPoint System:
AAV2-hAADC for Parkinson's disease Phase 1 Study at UCSF Initial sponsorship by Michael J. Fox Foundation AAV2-GDNF for
Parkinson's disease Phase 1 Study at the NIH MDNA55 for Recurrence or Progression of Glioblastoma Preparing Phase 2 Human
Parthenogenetic Stem Cell-Derived Neural Stem Cells for Parkinson's disease Pre-clinical leading to Ph. 1 IL13 for Brain
Tumor Phase 1 study at the NIH Radio Immunotherapy for Brain Tumor Phase 1 Study at MSK Nanoliposomal Irinotecan for Brain Tumor
Phase 1 Study at UCSF The ClearPoint System is being used in the ongoing Phase 1b clinical trial of VY-AADC01 as a treatment
for advanced Parkinson's disease, and we expect to continue to use the ClearPoint System in future clinical trials of VY-AADC01
and any other of our product candidates that are injected directly into the brain. IPO S-1, Voyager Therapeutics 2016
MRI INTERVENTIONS, INC. | 14
Revenue Model BUSINESS MODEL - RAZOR/RAZORBLADE ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables:
$7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered
by existing inpatient DRG reimbursement codes 2016 MRI INTERVENTIONS, INC. | 15
the ClearPoint Footprint Installed Base of 44 sites in the US Europe: Warsaw, Poland 2016 MRI INTERVENTIONS, INC.
US Market Opportunity Total Prevalence (US) Prevalence - Drug Treatment Resistant (DTR) Incidence - DTR ClearPoint
Enabled Therapy Potential ClearPoint Procedures, Annually2 Parkinson's 1,500,000 125,000 7,500 Electrode Placement
(DBS) 12,500 Epilepsy 2,200,000 264,000 18,000 Laser Ablation RNS1 28,000 Brain Tumors 80,000 (annual diagnosis)
Resections: 80,000 Stereotactic Biopsy: 10,000 Biopsy / Laser Ablation / Drug Delivery 14,500 55,000+ Potential Procedures
Per Year Note: Prevalence and Incidence based on either market research conducted by a third party on behalf of MRI Interventions
or research conducted by MRI Interventions of publicly available sources. (1) Responsive neurostimulation device (RNS) (2) Potential
Annual ClearPoint Procedures based upon 5% of prevalence and 85% of incidence; Potential Annual ClearPoint Procedures for brain
tumors based on market research conducted by a third party on behalf of MRI Interventions. 2016 MRI INTERVENTIONS, INC.
Consumable Revenues Consumables $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q3 Q4 2013 Q1 Q2 Q3 Q4 2014 Q1 Q2
Q3 Q4 2015 Q1 Q2 2016 2016 MRI INTERVENTIONS, INC. | 18
Revenue, 2013 - 2016 Total Revenue $1,600,000 $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1
Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2013 2014 2015 2016 Consumables Capital / Service Other 2016 MRI INTERVENTIONS,